Cingulate (CING) Stock: Buy, Sell, or Hold?
CING - Cingulate Inc. Common Stock
$4.98
0.32 (6.87%)
▲
5d:
+14.22%
30d:
-1.58%
90d:
+10.18%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
18d
Get Alerted When CING Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CING shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CING shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: CING is currently trading at $4.98, which is considered slightly high relative to its 30-day fair value range of $4.60 to $5.08.
Technical Outlook: Technically, CING is showing sideways momentum. The price is approaching resistance at $4.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: CING scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.20 (+325.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CING is showing sideways momentum. The price is approaching resistance at $4.98. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.9% recently.
Market Sentiment: CING scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $21.20 (+325.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.60 -
$5.08
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.5%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.9%)
- BULLISH: Trading 325.7% below Wall St target ($21.20)
- BULLISH: Bottoming setup score 71/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$4.60 -
$5.08
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.60
(12.0%)
Support & Resistance Levels
Support Level
$4.12
Resistance Level
$4.98
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.66
Wall Street Target
$21.20
(+325.7%)
Share & Embed Analysis
Last updated: October 24, 2026 12:03 AM ET
Data refreshes hourly during market hours. Next update: 1:03 AM
Data refreshes hourly during market hours. Next update: 1:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CING showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 47 HOLD |